Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report.
We studied the recurrence rate of pterygium after administration of a single dosage of topical mitomycin C at the completion of pterygium surgery. Forty patients who had advanced or recurrent pterygium underwent excision of pterygium, leaving the sclera bare. Patients were randomized in a masked fashion into two groups of 20 patients each. Group 1 received a single dosage of topical 0.02% mitomycin C for 5 min at the completion of the surgery whereas group 2 underwent the same procedure but received NaCl 0.9% instead of mitomycin C. Patients were followed from 6 to 15 months in a masked manner. The pterygium recurred in one patients (5%) in group 1, whereas in group 2 the recurrence rate was 45% (p = 0.0035). Formation of dellen and a delay of epithelialization for 5 weeks were found in one patient in group 2. No complications were observed in patients in group 1. This study indicates the possible advantage of administration of a single dosage of 0.02% mitomycin C for postoperative prevention of recurrence of pterygium.
Frucht-Pery
J
J
Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
Ilsar
M
M
Hemo
I
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009883:Ophthalmic Solutions; D010865:Pilot Projects; D011183:Postoperative Complications / Q000517:prevention & control; D011625:Pterygium / Q000517:prevention & control* / Q000601:surgery*; D012008:Recurrence
D009883:Ophthalmic Solutions; D016685:Mitomycin